Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-08-22 Legal Proceedings Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Legal Proceedings Report 2019
Legal Proceedings Report Classification · 99% confidence The document is titled "Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan" and is explicitly labeled as a "Company Announcement." It details a regulatory event (drug approval by the MHLW in Japan) and the resulting financial milestone payment. This type of announcement, which communicates significant corporate news, regulatory milestones, or clinical trial results outside of the standard periodic financial reports (like 10-K or IR), typically falls under general Regulatory Filings (RNS) or, if it were a more detailed management discussion, potentially MDA. However, since it is a specific, time-sensitive announcement of a regulatory/commercial event, and not a standard periodic report, a general regulatory announcement code is most appropriate. It is not an Earnings Release (ER) as it doesn't focus on period financials, nor is it a Call Transcript (CT) or Investor Presentation (IP). Given the options, RNS (Regulatory Filings - general regulatory announcements) is the best fit for a press release announcing a specific regulatory approval and milestone payment.
2019-08-22 English
6-K
Foreign Filer Report
2019-08-21 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab A/S regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting total share capital. This falls under the category of share issuance or capital changes. While it mentions an attachment, the text itself provides the full details of the transaction, making it a primary announcement of a capital change rather than just a notification of a report publication.
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab A/S regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting total share capital. This falls under the category of share issuance or capital changes. While it mentions an attachment, the text itself provides the full details of the transaction, making it a primary announcement of a capital change rather than just a notification of a report publication.
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab A/S regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting total share capital. This falls under the category of share issuance or capital changes. While it mentions an attachment, the text itself provides the full details of the transaction, making it a primary announcement of a capital change rather than just a notification of a report publication.
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab A/S regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting total share capital. This falls under the category of share issuance or capital changes. While it mentions an attachment, the text itself provides the full details of the transaction, making it a primary announcement of a capital change rather than just a notification of a report publication.
2019-08-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.